Insight

Novel PARP inhibitor saruparib in metastatic hormone-sensitive prostate cancer

Photo taken from UroToday/X

Jun 24, 2024, 01:48

Novel PARP inhibitor saruparib in metastatic hormone-sensitive prostate cancer

UroToday shared a post on X: .

“The EvoPAR-Prostate 01 Trial: Novel PARP inhibitor saruparib in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).

Neeraj Agarwal from Huntsman Cancer Institute and Zach Klaassen from Georgia Cancer Center discuss this new PARP inhibitor combined with ARPI in both biomarker-positive and negative populations.”

Proceed to the video.
Source: UroToday/X

ARPI cancer EvoPAR-Prostate 01 Trial Georgia Cancer Center Huntsman Cancer Institute Metastatic Hormone-sensitive Prostate Cancer mHSPC Neeraj Agarwal OncoDaily Oncology PARP inhibitor saruparib Zach Klaassen

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage